实用妇产科杂志2011，Vol.27Issue(9)：674-677,4.
血清CYFRA21-1与宫颈癌患者临床病理特征及预后的关系
Relationship of Serum CYFRA21-1 Level and Clinicopathologic Features of Patients with Cervical Carcinoma
摘要
Abstract
Objective:To investigate the relationship between pretreatment serum cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) level and the clinicopathologic features of cervical carcinoma. Methods: Pretreatment serum level of CYFRA21 -1 in 90 patients with FIGO I B1 ~ TJ B cervical cacinoma were checked, the correlations of this factor with clinico-pathothological features and prognosis were retrospectively analyzed. Results:The range of the serum level of CYFRA21-1 in 90 patients was 0. 61 -30. 30 mg/L, was 3.15 ±3. 57 mg/L. Elevation of CYFRA21 -1 was found in 26. 7% of patients using a cut-off value of 3. 3mg/ L. The mean value and elevation rate of CYFRA21-1 in patients with different FIGO stages, tumor size, gross type, pathological type, with or without pelvic lymph node metastasis, deep cervical stromal invasion or lymphvascular space invasion were not significant P>0.05). With a median follow-up of 42 months, CY-FRA21-1 value(0.10 -3.30 mg/L vs >3. 30 mg/L) was not significantly correlated with recurrence rate (19.7% vs25.0%, P>0.05). Preteatment CYFRA21-1 value had no predictive value for recurrence(AUC = 0.456 ±0.087). CYFRA21 -1 level (elevated vs not elevated) was not corrlated with overall survival(79.0% vs 82.0%, P>0. 05 ). Conclusions: Among patients with FIGO stage I B1 -TJ B cervical carcinoma, the elevation of serum CYFRA21-1 has no correlation with clinico-pathological features, recurrence and survival rate.关键词
宫颈癌/CYFRA21-1/预后Key words
Cervical carcinoma/ Cytokeratin 19 fragment antigen 21-1/ Prognosis分类
医药卫生引用本文复制引用
熊樱,梁立治,郑敏,刘继红..血清CYFRA21-1与宫颈癌患者临床病理特征及预后的关系[J].实用妇产科杂志,2011,27(9):674-677,4.基金项目
广东省科技计划项目(编号:2007 B060401071) （编号:2007 B060401071）
